References
Doody RS, Stevens JC, Beck C, et al.: Practice parameter: management of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1154–1166.
McKeith I, Del Ser T, Spano PE, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo controlled international study. Lancet 2000, 356:2031–2036.
Tariot PN, Solomon PR, Morris JC: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000, 54:2269–2276.
Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study group. Neurology 2000, 54:2261–2268.
Le Bars PL, Katz MM, Berman N, et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementa. North American Egb Study Group. JAMA 1997, 278:1327–1332.
van Dongen MC, van Rossum E, Kessels AG, et al.: The efficacy of gingkgo for elderly people with dmentia an dage-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000, 48:1183–1194.
European Pentoxifyline Multi-Infarct Dementia (EPMID) Study Group: European Pentoxyifylline Multi-Infarct Dementia Study. Eur Neruol 1996, 36:315–321.
Black R, Barclay L, Nolan K, et al.: Pentoxifylline in cerebrovascular dmentia. J Am Geriatr Soci 1992, 40:237–244.
Kumar V, Anand R, Messina J, Hartman R, Veach J: An efficacy and safety analysis of Exelon in Alzheimr’s disease patients with concurrent vascular risk factors. Eur J Neurol 2000, 7:159–169.
Ebmeier KP, Calder SA, Crawford JR, et al.: Dementia in idiopathic Parkinson’s disease: prevalence and relationship with symptoms and signs of parkinsonism. Psychol Med 1991, 21:69–76.
Mayeux R, Denaro J, Hemenegildo N, et al.: A populationbased investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 1992, 49:492–497.
Tison F, Dartigues JF, Auriacombe S, et al.: Dementia in Parkinson’s disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995, 45:705–708.
Marder K, Tang MX, Cote L, Stern Y, Mayeux R: The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 1995, 52:695–701.
Aarsland D, Tandberg E, Larsen JP, Cummings JL: Frequency of dementia in Parkinson disease. Arch Neurol 1996, 53:538–542.
Hurtig HI, Trojanowski JQ, Galvin J, et al.: Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000, 54:1916–1921.
Rights and permissions
About this article
Cite this article
Marder, K. Cholinesterase inhibitors in dementia. Curr Neurol Neurosci Rep 2, 390–391 (2002). https://doi.org/10.1007/s11910-002-0063-9
Issue Date:
DOI: https://doi.org/10.1007/s11910-002-0063-9